title: Verapamil in infants: an exaggerated fear?
abstract: The use of intravenous verapamil for tachyarrhythmia in infants is widely considered contraindicated due to the perceived risk of hemodynamic collapse after administration. This article reviews the relatively limited evidence that led to this well-known contraindication and highlights the interesting process by which medical practice may evolve in the absence of persuasive science.
authors.affiliation: Department of Pediatrics and Communicable Diseases, CS Mott Children's Hospital, University of Michigan, 1540 E. Hospital Drive, Ann Arbor, MI, 48109, USA, mlapage@med.umich.edu.
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Lapage
authors.forename: David J
authors.initials: DJ
authors.lastname: Bradley
authors.forename: Macdonald
authors.initials: M
authors.lastname: Dick
mesh_terms: D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D014943:Global Health; D007722:Health Knowledge, Attitudes, Practice; D006333:Heart Failure / Q000139:chemically induced* / Q000453:epidemiology / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D015994:Incidence; D007223:Infant; D012307:Risk Factors; D013610:Tachycardia / Q000188:drug therapy* / Q000503:physiopathology; D014700:Verapamil / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D002121:Calcium Channel Blockers; D014700:Verapamil